2023年5月31日 | 28:55 min.
Article series – 3 / 3 观点
The EC pharma and patent package – what’s important to know from a patent law perspective?
End of April, the European Commission presented its draft for a comprehensive reform of pharmaceutical legislation as well as draft regulations that provide for a unitary SPC, a centralised application for “classic” SPCs and an EU wide compulsory license.
It is planning the biggest pharmaceutical reform in 20 years. In particular, the SPC system is to be simplified and streamlined, an EU wide compulsory licensing system shall be implemented in order to tackle future crises and emergencies and questions regarding the possibility to rely on Bolar exemptions are to be clarified.
But what can companies in the sector expect and what issues should they be aware of? Get an overview here.
Download our presentation "The EC pharma and patent package"
Download our presentation: The EC pharma and patent package
The European Commission's pharmaceutical reform package
core objectives and planned changes at a glance
Read the entire article本系列内容
The EC pharma and patent package – what’s important to know from a patent law perspective?
2023年5月31日
作者 作者
Related Insights
Supplementary protection certificates: where are we and where are we going? (an update)
相关活动